Sorafenib plus partial splenic embolism for treatment of hepatocellular carcinoma Barcelona stage C combined with hypersplenism: a case series

BACKGROUND: Sorafenib is mainly used to treat patients with hepatocellular carcinoma (HCC) Barcelona Clinic Liver Cancer (BCLC) stage C, many of whom also have severe cirrhosis. However, hypersplenism and digestive tract hemorrhage are common complications of cirrhosis, which increase the risk and d...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Jianting, Wang, Chunmei, Wang, Yu, Luo, Zhenhua, Zhang, Yanlin, Luo, Xianzhang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216376/
https://www.ncbi.nlm.nih.gov/pubmed/34139869
http://dx.doi.org/10.1177/03000605211023351

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216376/
https://www.ncbi.nlm.nih.gov/pubmed/34139869
http://dx.doi.org/10.1177/03000605211023351

Ejemplares similares